Erratum

Erratum: FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice

Timothy D. Rohrbach, Amon Asgharpour, Melissa A. Maczis, David Montefusco, L. Ashley Cowart, Pierre Bedossa, Arun J. Sanyal, and Sarah Spiegel

VOL 60 (2019) PAGES 1311–1322

Potential conflicts of interest were inadvertently omitted. Dr. Sanyal has served as a consultant to Astra Zeneca, Bristol Myers Squibb, Conatus, Allergan, Merck, Genentech, Birdrock, 89Bio, Poxel, Surrozen, Gilead, Boehringer-Ingelhiem, Siemens, Sanofi, Lipocine, Madrigal, Glymple, Ferring, Artham, Terns, Lilly, Novartis, Novo Nordisk, and Pfizer. He has served as an unpaid advisor to Exhalenz, Valeant, Intercept, Echosense, Immuron, Fortress Labs, Metacrine, Cirius, Galectin, Pliant, Fractyl, Northsea Pharma, Gencia, BiocellBio, Path AI, Affimune, Histoindex, Chemomab, Blade, Nordic Bioscience, and Zydus. His institution has received grant support from Gilead, Salix, Bristol Myers Squibb, Tobira, Shire, Intercept, Merck, Astra Zeneca, Mallinckrodt, Cumberland, and Novartis. Dr. Sanyal receives royalties from Elsevier and UptoDate. He is the President of Sanyal Biotechnology and has stock options in Genfit, Akarna, Tiziana, Indalo, Durect, and Inversago. VCU has ownership interests in Sanyal Biotechnology.

DOI https://doi.org/10.1194/jlr.ERR119000580

Copyright © 2020 by the American Society for Biochemistry and Molecular Biology, Inc.